1 / 16

Improving bone and cardiovascular health

NattoPharma focuses on improving bone and cardiovascular health through the development and sales of natural Vitamin K2. The company has exclusive partnerships with Sumitomo Corp and VitaK for research, development, and market access. Their products have documented beneficial effects on osteoporosis and cardiovascular diseases.

rmaggie
Download Presentation

Improving bone and cardiovascular health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Improving bone and cardiovascular health Investor Presentation 1. Quarter 2008

  2. Exclusive strategic partnership agreement with Sumitomo Corp. to develop, market and sell the natural Vitamin K2 • Exclusive Research & Science contract with VitaK (Maastricht University), the world leading research-company in vitamin K. • R&D is focused on developing K2 products in addition to build IPR to secure long-term market access • Vitamin K2 is needed for optimal body utilization of Calcium and has documented beneficial effects on both Osteoporosis and Cardiovascular diseases

  3. NattoPharma focuses on Sales & Product Development, through own Product IPR- based on clinical studies (GCP), leaving the production to Sumitomo. • Product development may also be carried out in collaboration with End-clients, depending upon customer and market requirements. End-client Sumitomo Corp. Production & Process IPR Clinical Studies IPR Product- Development Based on research Product-design End-product S&M NattoPharma

  4. Teeth Calcification in health and disease:NattoPharma focus - + Lungs Kidneys + + • Scientific evidence: • Loss of calcification in bones; • Increased calcification heart, • arteries and in joints: • Osteoporosis • Cardiovascular disease • Osteoarthrosis Bone and cardiovascular health Normal condition: 99% of all Ca in bones & teeth; 1% in circulation Prevention & Treatment

  5. The calcium paradox Relationship osteoporosis - arterial calcification Function of both proteins needed for optimal health Osteocalcin Matrix Gla Protein • MGP synthesised in • chondrocytes in • cartilage, and vascular • smooth muscle cells in • arteries • Inhibits soft tissue • calcification, including • cartilage mineralization • OC synthesised in osteoblasts • Glu residues carboxylated • to Gla-residues which bind Ca++ • Binds Ca++ to hydroxyapatite in bones x x x

  6. Market opportunities • NattoPharma market strategy • NattoPharma is working to include vitamin K2 in already existing global leading brands in the Dietary supplement (ex. Multivitamins, Calsium & Omega3) Functional Food marked (Dairy-products). Thus, the revenue from the clients has the potential to go from zero to 3-diget million figure, only during the first year after signing with a large client. • Dietary supplement • Stand-alone / combination (Multivitamins, Calcium, Omega-3 and Vitamin D) • Fortified food • Fortified food with vitamins and minerals (Dairy segment, drinks) • Pharmacy • Strategy is to co-operate with a strategic partner

  7. Market strategy Sell MenaQ7 as an ingredients into all ready existing global leading brands in the following market segments: Pharmacy Volum vitamin K2 Fortified Food Dietary supplement 2007 2008 2009 2010 2011 2012 2013

  8. Headlines 1Q08 R&D: • Commenced clinical study combining MenaQ7 with Omega- and with Krill • Longtime study approved and ready to start for postmenopausal 240 women to see MenaQ7’s effect on bone structure and cardio vascular effects.

  9. Headlines 1Q08 MARKET: • Have signed distribution agreements in all European countries that we are able to MenaQ7 • Focus on Food segment both in USA. Official launch of MenaQ7 in Food at world larges Food Fair, Institute of Food Technology 2008 in New Orleans. • Screening the market outside Europe and USA for potential distributors

  10. Strategic Partnership Agremments • LOI sign with Bayer ConsumerCare • Bayer is no. 2 largest player in the global OTC market • The Parties wants to negotiate about signing a global partnership agreement for MenaQ7. • In search for a global partner also in the Food Market

  11. Figures 1. quarter 2008 Revenues NOK 5,1m (NOK 7,4m) EBIT NOK -5,9m (NOK -0,8m) Gross margin 55,1% (56,4%)

  12. Profit and Loss pr.31.03.2008

  13. Balance pr. 31.03.2008

  14. Balance pr. 31.03.2008

  15. Cash flow statement Q1 - 2008

  16. Outlook • Expect EFSA approval during the summer • Increase the investment in R&D going forward • Reiterate revenue expectation for 2008 of between NOK 80 – 90 mill in 2008 • Expect positive EBIT in 2008

More Related